Relieving Nasal Congestion in Children with Seasonal and Perennial Allergic Rhinitis: Efficacy and Safety Studies of Mometasone Furoate Nasal Spray

Overview

Journal World Allergy Organ J

Specialty Allergy & Immunology

Date 2013 May 14

PMID 23663488

Citations 3

Authors

Eli O Meltzer

Carlos E Baena-Cagnani

Davis Gates

Ariel Teper

Affiliations

Soon will be listed here.

Abstract

Background: In surveys of children with allergic rhinitis (AR), nasal congestion has been identified as the most frequently experienced and bothersome symptom. This analysis was conducted to investigate the effect of mometasone furoate nasal spray (MFNS) on congestion in children with AR.

Methods: Two multicenter, double-blind, placebo-controlled studies randomly assigned children to MFNS 100 μg or placebo, 1 spray/nostril QD for 4 weeks (Study 1: ages 6-11 years with seasonal AR [SAR] ≥1 year; Study 2: ages 3-11 years with perennial AR [PAR] ≥1 year). Least square (LS) means were obtained from an ANCOVA model with treatment and study center effects, with baseline score as a covariate. We conducted post hoc evaluation of changes from baseline in AM/PM PRIOR (average of reflective AM and PM scores) nasal congestion (0=none to 3=severe).

Results: Study 1: MFNS (n=134) reduced congestion significantly more than placebo (n=135) on day 2 (P=.004) and on 23/29 days (P≤.037). Change from baseline was -0.53 and -0.28 for MFNS and placebo (P<.001) over days 1-15 and -0.64 and -0.38 for MFNS and placebo (P<.001) over days 1-29. Study 2: MFNS (n=185) reduced congestion significantly more than placebo (n=189) on day 3 (P=.015) and on 22/29 days (P≤.047). Change from baseline was -0.56 and -0.36 for MFNS and placebo (P<.001) over days 1-15 and -0.64 and -0.45 for MFNS and placebo (P<.001) over days 1-29. MFNS was well tolerated, with no unusual or unexpected adverse events.

Conclusion: MFNS effectively relieved nasal congestion and was well tolerated in children with SAR or PAR.

Citing Articles

Nasal Absorption Enhancement of Mometasone Furoate Nanocrystal Dispersions.

Masuda S, Deguchi S, Ogata F, Yoshitomi J, Otake H, Kanai K Int J Nanomedicine. 2023; 18:5685-5699.

PMID: 37841023 PMC: 10573391. DOI: 10.2147/IJN.S430952.

Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).

Ecevit M, Ozcan M, Haberal Can I, Tatar E, Ozer S, Esen E Turk Arch Otorhinolaryngol. 2021; 59(Suppl 1):1-157.

PMID: 34212158 PMC: 8221269. DOI: 10.4274/tao.2021.suppl.1.

Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma.

Dixon A, Castro M, Cohen R, Gerald L, Holbrook J, Irvin C J Allergy Clin Immunol. 2014; 135(3):701-9.e5.

PMID: 25174863 PMC: 4344935. DOI: 10.1016/j.jaci.2014.06.038.

References

Abreu R, Rocha R, Lamounier J, Guerra A . Etiology, clinical manifestations and concurrent findings in mouth-breathing children. J Pediatr (Rio J). 2008; 84(6):529-35. DOI: 10.2223/JPED.1844. View

Juliano M, Machado M, Bizari Coin de Carvalho L, Zancanella E, Santos G, Bizari Fernandes do Prado L . Polysomnographic findings are associated with cephalometric measurements in mouth-breathing children. J Clin Sleep Med. 2010; 5(6):554-61. PMC: 2792972. View

Juliano M, Machado M, Bizari Coin de Carvalho L, Bizari Fernandes do Prado L, do Prado G . Mouth breathing children have cephalometric patterns similar to those of adult patients with obstructive sleep apnea syndrome. Arq Neuropsiquiatr. 2009; 67(3B):860-5. DOI: 10.1590/s0004-282x2009000500015. View

Shedden A . Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir Med. 2005; 4(6):439-46. DOI: 10.2165/00151829-200504060-00007. View

Brozek J, Bousquet J, Baena-Cagnani C, Bonini S, Canonica G, Casale T . Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126(3):466-76. DOI: 10.1016/j.jaci.2010.06.047. View

Ciprandi G, Cirillo I, Vizzaccaro A, Tosca M, Passalacqua G, PALLESTRINI E . Seasonal and perennial allergic rhinitis: is this classification adherent to real life?. Allergy. 2005; 60(7):882-7. DOI: 10.1111/j.1398-9995.2005.00602.x. View

Modrzynski M, Zawisza E . An analysis of the incidence of adenoid hypertrophy in allergic children. Int J Pediatr Otorhinolaryngol. 2007; 71(5):713-9. DOI: 10.1016/j.ijporl.2006.12.018. View

Scadding G, Richards D, Price M . Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol Allied Sci. 2000; 25(6):551-7. DOI: 10.1046/j.1365-2273.2000.00417.x. View

Sibbald B, Rink E . Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax. 1991; 46(12):895-901. PMC: 463495. DOI: 10.1136/thx.46.12.895. View

10.

Baena-Cagnani C, Patel P . Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin. 2010; 26(9):2047-55. DOI: 10.1185/03007995.2010.487661. View

11.

de Freitas FCN , Bastos E, Primo L, de Freitas V . Evaluation of the palate dimensions of patients with perennial allergic rhinitis. Int J Paediatr Dent. 2001; 11(5):365-71. DOI: 10.1046/j.0960-7439.2001.00292.x. View

12.

Meltzer E, Blaiss M, Derebery M, Mahr T, Gordon B, Sheth K . Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol. 2009; 124(3 Suppl):S43-70. DOI: 10.1016/j.jaci.2009.05.013. View

13.

Brannan M, Herron J, Affrime M . Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther. 1998; 19(6):1330-9. DOI: 10.1016/s0149-2918(97)80008-2. View

14.

Meltzer E, Shekar T, Teper A . Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2011; 32(2):159-67. DOI: 10.2500/aap.2011.32.3424. View

15.

Mansfield L, Diaz G, Posey C, Flores-Neder J . Sleep disordered breathing and daytime quality of life in children with allergic rhinitis during treatment with intranasal budesonide. Ann Allergy Asthma Immunol. 2004; 92(2):240-4. DOI: 10.1016/S1081-1206(10)61554-2. View

16.

Wandalsen G, Mendes A, Sole D . Objective improvement in nasal congestion and nasal hyperreactivity with use of nasal steroids in persistent allergic rhinitis. Am J Rhinol Allergy. 2010; 24(1):e32-6. DOI: 10.2500/ajra.2010.24.3427. View

17.

Martins da Silva C, Silva T, Morales N, Fernandes K, Pinto R . Quality of life in children and adolescents with allergic rhinitis. Braz J Otorhinolaryngol. 2009; 75(5):642-9. PMC: 9442187. View

18.

Li A, Au C, So H, Lau J, Ng P, Wing Y . Prevalence and risk factors of habitual snoring in primary school children. Chest. 2010; 138(3):519-27. DOI: 10.1378/chest.09-1926. View

19.

Bousquet J, Van Cauwenberge P, Khaltaev N . Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001; 108(5 Suppl):S147-334. DOI: 10.1067/mai.2001.118891. View

20.

Meltzer E, Berger W, Berkowitz R, Bronsky E, Dvorin D, Finn A . A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1999; 104(1):107-14. DOI: 10.1016/s0091-6749(99)70121-1. View